Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 1 Historical and established therapies

Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS)

“…In Australia, the license also pertains to patients with secondary progressive MS (SPMS) with residual inflammatory activity (Broadley et al, 2014;Freedman et al, 2013).…”

The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews

“…Disease-modifying therapies aim to lessen the number, severity and duration of relapses, maintain remission, and slow progression. These therapies are usually immunomodulatory and/or immunosuppressive treatments such as, interferon beta, copaxone, fingolimod, natalizumab and alemtuzumab [5][6][7]. Symptomatic therapies that relieve the distressing and/or disabling symptoms of multiple sclerosis include: anticonvulsants for neuropathic pain, anticholinergic drugs for bladder dysfunction and dysphagia, and botulinum toxin injections for spasticity [1].…”

Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data

“…The factors associated with this encouraging improvement are largely unclear but increased availability of more potent DMTs may be an important contributor 13. However, the differential effects of currently available DMTs on improving work ability for people with MS remains unknown.…”